Related Experiment Videos
Nonradioactive ligand binding assay for epidermal growth factor receptor
1Department of Experimental Therapeutics, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492.
Analytical Biochemistry
|July 1, 1990
Summary
A novel, nonradioactive assay quickly identifies epidermal growth factor receptor (EGFR) agonists and antagonists. This sensitive method is ideal for large-scale screening, offering reliable results without radioactive materials.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- The epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
- Accurate identification of EGFR agonists and antagonists is crucial for drug development.
- Existing ligand binding assays may involve radioactive substances or lack sensitivity for large-scale screening.
Purpose of the Study:
- To develop and validate a rapid, sensitive, and nonradioactive ligand binding assay for EGFR.
- To enable efficient screening of potential EGFR modulators.
Main Methods:
- A 96-well plate-based assay was developed.
- The assay utilizes nonradioactive detection methods.
- Assay validity was assessed through rigorous testing and comparison with established methods.
Main Results:
- The assay demonstrated a within-assay error of less than 15%.
- Nonspecific binding was consistently below 10%.
- The assay detected EGFR antagonists at concentrations as low as 10 nM (with equivalent affinity to EGF).
Conclusions:
- A robust, nonradioactive ligand binding assay for EGFR has been established.
- The assay is suitable for high-throughput screening of EGFR agonists and antagonists.
- This method offers a sensitive and practical alternative for drug discovery research.